Physician profile
Robert Gousse
NPI 1952667792
$2,495.55
in general payments reported to CMS, 2019-2025
25 companies · $991 in 2025
The $991 reported for 2025 was more than what 90% of Sports Medicine (Family Medicine) providers received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.63 · 2022: $57.84 · 2023: $373 · 2024: $1,005 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,369.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,369.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $481.21 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $361.07 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $243.02 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $207.34 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $163.84 | 2019-2025 | Otezla, Repatha, Krystexxa |
| Pfizer INC. | $162.69 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.62 | 2022-2025 | Trintellix |
| Kowa Pharmaceuticals America, INC. | $104.55 | 2023-2025 | Zoryve, Seglentis, Livalo |
| Orthofix Medical, INC. | $94.68 | 2025 | Physio-Stim |
| Painteq LLC | $78.01 | 2024 | Painteq |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.03 | 2023-2024 | Xifaxan |
| Bioventus LLC | $71.19 | 2022-2024 | Exogen Ultrasound Bone Healing System, Durolane |
| Vertex Pharmaceuticals Incorporated | $62.88 | 2024-2025 | |
| Exact Sciences Corporation | $50.21 | 2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.68 | 2023-2024 | Jardiance |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $28.81 | 2024 | |
| Abbott Laboratories | $26.79 | 2025 | Freestyle Libre 3 |
| Seqirus USA INC | $21.18 | 2025 | Fluad, Flucelvax |
| Esperion Therapeutics, INC. | $17.46 | 2023 | Nexletol |
| Arbor Pharmaceuticals, INC. | $16.73 | 2019 | |
| Fidia Pharma USA INC. | $15.09 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.18 | 2022 | |
| Dexcom, INC. | $14.17 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $14.12 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$150,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Gousse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.